Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment

Digestive Endoscopy

Volumn 26, Issue 1, 2014, Pages 1-14

  Fujimoto, Kazuma ^a   Fujishiro, Mitsuhiro ^a   Kato, Mototsugu ^a   Higuchi, Kazuhide ^a   Iwakiri, Ryuichi ^a   Sakamoto, Choitsu ^a   Uchiyama, Shinichiro ^b,c,d   Kashiwagi, Atsunori ^e   Ogawa, Hisao ^f   Murakami, Kazunari ^a   Mine, Tetsuya ^a   Yoshino, Junji ^a   Kinoshita, Yoshikazu ^a   Ichinose, Masao ^a   Matsui, Toshiyuki ^a  

^a Japan Society for Respiratory Endoscopy   (Japan)

^b Optical Society of Japan   (Japan)

^c Japan Stroke Society   (Japan)

^d Japanese Society on Thrombosis and Hemostasis Post Marketing Surveillance Committee for Recomodulin Injection   (Japan)

^e Japanese Geotechnical Society   (Japan)

^f Cardiac Transplantation Committee of the Japanese Circulation Society   (Japan)

Author keywords

anticoagulant; antiplatelet agent; gastroenterological endoscopic examination and treatment; gastroenterological hemorrhage; thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; DABIGATRAN; HEPARIN; THIENOPYRIDINE DERIVATIVE; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HUMAN; INCIDENCE; JAPAN; PRACTICE GUIDELINE; THROMBOEMBOLISM;

ANTICOAGULANT; ANTIPLATELET AGENT; GASTROENTEROLOGICAL ENDOSCOPIC EXAMINATION AND TREATMENT; GASTROENTEROLOGICAL HEMORRHAGE; THROMBOEMBOLISM;

ASPIRIN; ENDOSCOPY, GASTROINTESTINAL; FIBRINOLYTIC AGENTS; GASTROINTESTINAL HEMORRHAGE; HUMANS; JAPAN; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PROGRAM DEVELOPMENT; RISK FACTORS; SOCIETIES, MEDICAL;

EID: 84891627970     PISSN: 09155635     EISSN: 14431661     Source Type: Journal    
DOI: 10.1111/den.12183     Document Type: Article

References (67)

1. Japan Gastroenterological Endoscopy Society Postgraduate Education Committee. Guidelines for Gastroenterological Endoscopy. Japan Gastroenterological Endoscopy Society (ed.). Tokyo: Igaku Shoin, 1999. (in Japanese.)
2. Ogoshi K, Kaneko E, Tada M, et al. Japan Gastroenterological Endoscopy Society Risk Management Committee. Use of anticoagulants and antiplatelet agents during endoscopic procedures. Gastroenterol. Endosc. 2005; 47: 2691-2695. (in Japanese.)
3. Japan Gastroenterological Endoscopy Society Postgraduate Education Committee. Guidelines for Gastroenterological Endoscopy version 3. Japan Gastroenterological Endoscopy Society (ed.). Tokyo: Igaku Shoin, 2006. (in Japanese.)
4. 2008 Report of Joint Study Group. Guidelines on anticoagulant and antiplatelet therapy for cardiovascular illnesses 2009 revised edn. (in Japanese.) Available from URL: http://www.j-circ.or.jp/guideline/pdf/JCS2009- hori-d.pdf
5. Joint Guidelines Committee on Strokes. 2009 Stroke Therapy Guidelines., Shinohara Y, Ogawa A, Suzuki N, Katayama Y, Kimura A, (eds). Kyowa Kikaku, 2009. (in Japanese.)
6. Anderson MA, Ben-Menachem T, Gan SI, et al. Guidelines: Management of antithrombotic agents for endoscopic procedures. Gastrointest. Endosc. 2009; 70: 1060-1070.
7. Becker R, Scheiman J, Dauerman HL, et al. Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. Am. J. Gastroenterol. 2009; 104: 2903-2917.
8. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894-1909.
9. Veitch AM, Baglin TP, Gershlick AH, et al. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures. Gut 2008; 57: 1322-1329.
10. Boustière C, Veitch A, Vanbiervliet G, et al. Endoscopy and antiplatelet agents. European Society of Gastrointestinal Endoscopy (ESGE) guidelines. Endoscopy 2011; 43: 445-458.
11. Shiffman RN, Shekelle P, Overhage JM, et al. Standardized reporting of clinical practice guidelines: A proposal from the Conference on Guideline Standardization. Ann. Intern. Med. 2003; 139: 493-498.
12. Eddy DM,. Designing a practice policy: Standards, guidelines and options. JAMA 1990; 263: 3077-3082.
13. Ueno F, Matsui T, Matsumoto T, et al. Evidence-based clinical practice guidelines for Crohn's disease, integrated with formal consensus of experts in Japan. J. Gastroenterol. 2013; 48: 31-72.
14. Takada T, Hirata K, Mayuki T, et al. Cutting-edge information for the management of acute pancreatitis. J. Hepatobiliary Pancreat. Sci. 2010; 17: 3-12.
15. Becker RC, Scheiman J, Dauerman HL, et al. American College of Cardiology & American College of Gastroenterology: Management of platelet-directed pharmacotherapy in patients with atherosclerotic coronary artery disease undergoing elective endoscopic gastrointestinal procedures. J. Am. Coll. Cardiol. 2009; 54: 2261-2276.
16. Sibon I, Orgogozo JM,. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 2004; 62: 1187-1189.
17. Maulaz AB, Bezerra DC, Michel P, et al. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch. Neurol. 2005; 62: 1217-1220.
18. Wahl MJ,. Dental surgery in anticoagulated patients. Arch. Intern. Med. 1998; 158: 1610-1616.
19. Blacker DJ, Wijdicks EF, McClelland RL,. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology 2003; 61: 964-968.
20. Palareti G, Legnani C, Guazzaloca G, et al. Activation of blood coagulation after abrupt or stepwise withdrawal of oral anticoagulants-a prospective study. Thromb. Haemost. 1994; 72: 222-226.
21. Kaneko E, Munakata A, Iwao Y, et al. Preventing complications associated with colonic endoscopy. Gastroenterol. Endosc. 2003; 45: 1939-1945. (in Japanese.)
22. Eisen GM, Baron TH, Dominitz JA, et al. American Society for Gastrointestinal Endoscopy: Guidelines on the management of antithrombotic and antiplatelet therapy for endoscopic procedures. Gastrointest. Endosc. 2002; 55: 775-779.
23. Sieg A, Hachmoeller-Eisenbach U, Eisenbach T,. Prospective evaluation of complications in outpatients GI endoscopy: A survey among German gastroendoscopists. Gastrointest. Endosc. 2000; 51: 37-41.
24. Parra-Blanco A, Kaminaga N, Kojima T, et al. Hemoclipping for postpolypectomy and postbiopsy colonic bleeding. Gastrointest. Endosc. 2000; 51: 37-41.
25. Whitson MJ, Dikman AE, von Althann C, et al. Is gastroduodenal biopsy safe in patients receiving aspirin and clopidogrel? J. Clin. Gastroenterol. 2011; 45: 228-233.
26. Shiffman ML, Farrel MT, Yee YS,. Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDS. Gastrointest. Endosc. 1994; 40: 458-462.
27. Ono S, Fujishiro M, Hirano K, et al. Retrospective analysis on the management of anticoagulants and antiplatelet agents for scheduled endoscopy. J. Gastroenterol. 2009; 44: 1185-1189.
28. Tono S, Morita Y, Miura M, et al. Risks associated with endoscopic biopsy procedures undertaken while administering antiplatelet drugs. Gastroenterol. Endosc. 2011; 53: 3326-3335. (in Japanese.)
29. Ono S, Fujishiro M, Kanzaki H, et al. Conflicting clinical environment about the management of antithrombotic agents during the periendoscopic period in Japan. J. Gastroenterol. Hepatol. 2011; 26: 1434-1440.
30. Yousfi M, Gostout CJ, Baron TH, et al. Postpolypectomy lower gastrointestinal bleeding: Potential role of aspirin. Am. J. Gastroenterol. 2004; 99: 1785-1789.
31. Gerson LB, Triadafilopoulos G, Gage BF,. The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: A decision analysis. Am. J. Gastroenterol. 2000; 95: 1717-1724.
32. Gerson LB, Michaels L, Ullah N, et al. Adverse events associated with anticoagulation therapy in the periendoscopic period. Gastrointest. Endosc. 2010; 71: 1211-1217.
33. Choudari CP, Rajgopal C, Palmer KR,. Acute gastrointestinal haemorrhage in anticoagulated patients: Diagnoses and response to endoscopic treatment. Gut 1994; 35: 464-466.
34. Yamamoto T, Kuyama Y, Kozuma K, et al. Low-dose aspirin prolongs bleeding after gastric biopsy in Japanese patients. Thromb. Res. 2008; 122: 722-723.
35. Yamamoto T, Kuyama Y, Kozuma K, et al. Antiplatelet agents and bleeding time after endoscopic biopsy of the gastric antrum in Japanese patients. Dig. Endosc. 2010; 22: 250.
36. Kim JS, Lee KS, Kim YI, et al. A randomized crossover comparative study of aspirin, cilostazol and clopidogrel in normal controls: Analysis with quantitative bleeding time and platelet aggregation test. J. Clin. Neurosci. 2004; 11: 600-602.
37. Yanagisawa A, Sakata K, Miyagawa M, et al. Impact of ethyl icosapentate and ticlopidine combination therapy on hemorrhage time and platelet aggregation. Clin. Rep. 1992; 26: 3193-3198. (in Japanese.)
38. Mabe K, Hirayama M, Kato M,. Withdrawal of anticoagulants and antiplatelet agents during endoscopy. Gastroenterol. Endosc. 2010; 52: 2976-2984. (in Japanese.)
39. Li Y, Sha W, Nie Y, et al. Effect of intragastric pH on control of peptic ulcer bleeding. J. Gastroenterol. Hepatol. 2000; 15: 148-154.
40. Baron TH, Harewood GC,. Endoscopic balloon dilation of the biliary sphincter compared to endoscopic biliary sphincterotomy for removal of common bile duct stones during ERCP: A metaanalysis of randomized, controlled trials. Am. J. Gastroenterol. 2004; 99: 1455-1460.
41. Hussain N, Alsulaiman R, Burtin P, et al. The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents: A case-control study. Aliment. Pharmacol. Ther. 2007; 25: 579-584.
42. Mannen K, Tsunada S, Hara M, et al. Risk factors for complications of endoscopic submucosal dissection in gastric tumors: Analysis of 478 lesions. J. Gastroenterol. 2010; 45: 30-36.
43. Okada K, Yamamoto Y, Kasuga A, et al. Risk factors for delayed bleeding after endoscopic submucosal dissection for gastric neoplasm. Surg. Endosc. 2011; 25: 98-107.
44. Ono S, Fujishiro M, Niimi K, et al. Technical feasibility of endoscopic submucosal dissection for early gastric cancer in patients taking anti-coagulants or antiplatelet agents. Dig. Liver Dis. 2009; 41: 725-728.
45. Tsuji Y, Ohata K, Ito T, et al. Risk factors for bleeding after endoscopic submucosal dissection for gastric lesions. World J. Gastroenterol. 2010; 16: 2913-2917.
46. Metz AJ, Bourke MJ, Moss A, et al. Factors that predict bleeding following endoscopic mucosal resection of large colonic lesions. Endoscopy 2011; 43: 506-511.
47. Tounou S, Morita Y,. Risks associated with gastric and duodenal ESD under ongoing low dose aspirin therapy. Gastroenterol. Endosc. 2010; 53: 3326-3335. (in Japanese.)
48. Singh M, Mehta N, Murthy UK, et al. Postpolypectomy bleeding in patients undergoing colonoscopy on uninterrupted clopidogrel therapy. Gastrointest. Endosc. 2010; 71: 998-1005.
49. Uchiyama S, Demaerschalk BM, Goto S, et al. Stroke prevention by cilostazol in patients with atherothrombosis: Meta-analysis of placebo-controlled randomized trials. J. Stroke Cerebrovasc. Dis. 2009; 18: 482-490.
50. White RH, McKittrick T, Hutchinson R, et al. Temporary discontinuation of warfarin therapy: Changes in the international normalized ratio. Ann. Intern. Med. 1995; 1: 40-42.
51. Tsuji H,. Clinical thrombosis and hemostasis techniques for interns III: Appropriate use of heparin formulations. J. Thromb. Haemost. 2008; 19: 187-190. (in Japanese.)
52. Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: Mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119 (1 Suppl): 64S-94S.
53. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann. Intern. Med. 1997; 15: 133-136.
54. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch. Intern. Med. 1994; 154: 1449-1457.
55. The European Atrial Fibrillation Trial Study Group. The optimal anticoagulation therapy in patients with non-rheumatic atrial fibrillation and recent cerebral ischemia. N. Engl. J. Med. 1995; 333: 5-10.
56. Guerrouij M, Uppal CS, Alklabi A, et al. The clinical impact of bleeding during oral anticoagulant therapy: Assessment of morbidity, mortality and post-bleed anticoagulant management. J. Thromb. Thrombolysis 2011; 31: 419-423.
57. Hui AJ, Wong RM, Ching JY, et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: Analysis of 1657 cases. Gastrointest. Endosc. 2004; 59: 44-48.
58. Witt DM, Delate T, McCool KH, et al. Incidence and predictors of bleeding or thrombosis after polypectomy in patients receiving and not receiving anticoagulation therapy. J. Thromb. Haemost. 2009; 7: 1982-1989.
59. Garcia DA, Regan S, Henault LE, et al. Risk of thromboembolism with short-term interruption of warfarin therapy. Arch. Intern. Med. 2008; 14: 63-69.
60. Yasaka M, Minematsu K, Yamaguchi T,. Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation. Intern. Med. 2001; 40: 1183-1188.
61. Constans M, Santamaria A, Mateo J, et al. Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy. Int. J. Clin. Pract. 2007; 61: 212-217.
62. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N. Engl. J. Med. 2009; 361: 1139-1151.
63. Stangier J, Eriksson BI, Dahl OE, et al. Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J. Clin. Pharmacol. 2005; 45: 555-563.
64. Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: An analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. Circulation 2011; 123: 2363-2372.
65. Watabe H, Yamaji Y, Okamoto M, et al. Risk assessment for delayed hemorrhagic complication of colonic polypectomy: Polyp-related factors and patient-related factors. Gastrointest. Endosc. 2006; 64: 73-78.
66. Goto O, Fujishiro M, Kodashima S, et al. A second-look endoscopy after endoscopic submucosal dissection for gastric epithelial neoplasm may be unnecessary: A retrospective analysis of postendoscopic submucosal dissection bleeding. Gastrointest. Endosc. 2010; 71: 241-248.
67. Fujimoto K, Fujishiro M, Kato M, et al. Guidelines for gastroenterological endoscopy in patients undergoing antithrombotic treatment. Gastroenterol. Endosc. 2012; 54: 2075-2102. (in Japanese.)